Over the past 10 years, the therapeutic arsenal for inflammatory bowel disease has grown exponentially, from TNF inhibitors such as infliximab, to anti-integrins (e.g., vedolizumab) and anti-interleukins (e.g., ustekinumab, risankizumab) amongst other drug classes. Given that the monoclonal antibody therapies are generally immunogenic, there are several laboratory assays to monitor patients in reactive or proactive stages of response assessment.

This webinar will cover the laboratory tests available to monitor patients using monoclonal antibody therapies for treatment of inflammatory bowel disease. Focus will be shared between analytical approaches as well as literature and practice recommendations for tests results interpretation.

свернуть